Verapamil Heart Drug Approved: A Strategic Analysis

Zydus Lifesciences has achieved a significant milestone: the U.S. Food and Drug Administration (FDA) has given final approval to their Verapamil Hydrochloride Extended-Release Tablets. These tablets, available in 120 mg, 180 mg, and 240 mg dosages, are prescribed to lower high blood pressure. Successfully managing blood pressure is crucial in preventing severe health issues such as strokes and heart attacks.

• Zydus received FDA final approval for Verapamil tablets.
• Tablets treat high blood pressure effectively, a major risk factor.
• Dosages available: 120mg, 180mg, and 240mg.
• Production will occur in Baddi, Himachal Pradesh, India.
• Sales totaled $24.5 million in the US (Sept-2025 data).
• Significant market opportunity with potential for growth.

Production and Location

The Verapamil Hydrochloride Extended-Release Tablets will be manufactured at Zydus Lifesciences Ltd’s facility in Baddi, Himachal Pradesh, India. This strategic location allows for efficient production and supply chain management.

Market Performance

These tablets demonstrated robust sales in the United States, achieving an annual revenue of USD 24.5 million during the period of September 2025 (according to IQVIA data). This performance highlights the drug’s demand and market acceptance.

Strategic Implications

This FDA approval represents a strengthened position for Zydus Lifesciences within the cardiovascular medication market. The successful launch of Verapamil SR Extended-Release tablets provides a valuable addition to their portfolio.

Ultimately, this approval underscores the company’s commitment to developing and supplying vital medications addressing prevalent health concerns.

Effective cardiovascular drugs contribute significantly to public health and company profitability.